Comment :: ‘Cannot ignore the possibility of some consolidation now’
Traders should maintain their focus on stock selection as we are seeing a catch-up move in the sectors and stocks that were on the sidelines in recent months.
Also, avoid contrarian bets in anticipation of a major decline.
Views by: Ajit Mishra, SVP – Technical Research, Religare Broking
Comment :: ‘The RBI is poised to maintain its hawkish stance’
Despite potential challenges such as a possible uptick in food inflation and a volatile external environment, the RBI is poised to maintain its hawkish stance, keeping the repo rate steady at 6.5% for the fifth consecutive time this year.
Notably, in the affordable segment, where demand momentum has trailed the overall residential market, interest rate movements play a pivotal role. Ensuring stable interest rates becomes imperative in this vulnerable segment, serving as a crucial catalyst to address the housing gap and propel the real estate market forward.
Views by: Shishir Baijal, Chairman and Managing Director, Knight Frank India
ALERT :: Indoco Remedies receives tentative approval from USFDA for ANDA for Canagliflozin tablet
>> Canagliflozin improves glycemic control in adults with type 2 diabetes mellitus.
Nifty Smallcap 250 up 10.2% in November 2023, Nifty 500 rose 7%
Angel One zooms 10%, hits record high on solid biz performance in November
Tata Power soars 6%; hits new high after 20 months on positive outlook
ALERT:: Zydus Life gets USFDA nod for Methylene Blue Injection; stock marginally up
Zydus Lifesciences in an exchange filing said it received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Methylene Blue Injection, 10mg/2ml and 50mg/5ml.